Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) announced key management appointments: Thomas Taapken, Ph.D., joins as Chief Financial Officer starting October 1, 2020, and Jordan Zwick is promoted to Chief Strategy Officer. Prof. Niels C. Riedemann emphasized Taapken's extensive biopharmaceutical experience, which will aid the company's late-stage clinical programs, while Zwick's new role aims to enhance U.S. operations. Taapken expressed enthusiasm about leading InflaRx during its first Phase III trial for anti-C5a therapeutics, crucial for addressing chronic inflammatory diseases, including COVID-19 pneumonia.
InflaRx (Nasdaq: IFRX) has initiated the global Phase III trial of IFX-1 for severe COVID-19 pneumonia, with the first site now active in the Netherlands and approval in Germany. The trial aims to enroll approximately 360 critically ill patients and will assess 28-day all-cause mortality as the primary endpoint. Encouraging Phase II results, showing lower mortality and organ dysfunction rates, have been accepted for publication in The Lancet Rheumatology. IFX-1, targeting complement factor C5a, is also being explored for other indications.
InflaRx announced positive results from the Phase II portion of its Phase II/III trial for IFX-1 in COVID-19 pneumonia, showing a 28-day all-cause mortality rate of 13% for treated patients versus 27% in controls. They completed a meeting with the FDA regarding IFX-1 for hidradenitis suppurativa, receiving support for a Phase III program. The company reported cash and equivalents of €98.9 million as of June 30, 2020, and a net loss of €18.3 million, an improvement from €25.1 million in the same period of 2019. Financial metrics indicate reduced research and development expenses.
InflaRx (Nasdaq: IFRX) reported promising initial data from the Phase II trial of IFX-1, showing a 50% lower all-cause mortality rate in patients with severe COVID-19 pneumonia compared to best supportive care. The company plans to advance to a Phase III trial with around 360 patients, aiming for a primary endpoint of 28-day all-cause mortality. The Phase II trial revealed a mortality rate of 13% in the IFX-1 group versus 27% in the control group. Interim analysis for the Phase III trial is expected after enrolling 180 patients.